TY - JOUR
T1 - Prophylactic HPV vaccination
T2 - Past, present, and future
AU - Castle, P. E.
AU - Maza, M.
N1 - Funding Information:
The authors thank the Sage Analytica team, in particular Lone Simonsen and Lewis Kim, for their contribution to the study. GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also took in charge all costs associated with the development and publication of the present manuscript. The authors are grateful to all teams of GSK Vaccines for their contribution to this study, especially Robert Gardner (scientific writer), Archana Jastorff (scientific writer; XPE Pharma and Science, on behalf of GSK Vaccines), Els Tassenoy (global study manager; Harrison Clinical Research, on behalf of GSK Vaccines), and Dominique Rosillon (Biometrics). Finally, the authors thank Joanne Wolter (independent medical writer, on behalf of GSK Vaccines) for providing writing services and Bruno Dumont (Business and Decision Life Sciences, on behalf of GSK Vaccines) for editorial assistance and manuscript coordination. Virology data were sourced from Public Health England (formerly Health Protection Agency). The opinions expressed in this report are solely those of the authors. [www.clinicaltrials. gov identifier: NCT01520935] Gon?alo Matias, Dave J. Webb, John Logie, and Fran?ois Haguinet are employed by the GSK Group of Companies. Dave J. Webb and John Logie report ownership of stock options and/or restricted shares. Robert J. Taylor, Roger L. Lustig, and Cynthia Schuck-Paim report having received consulting fees from Sage Analytica LLC to perform this study, paid for by the GSK Group of Companies. Douglas M. Fleming reports personal fees from Sage Analytica, personal fees and non-financial support from the GSK Group of Companies during the conduct of the study.
Publisher Copyright:
Copyright © Cambridge University Press 2015.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Human papillomavirus (HPV) is the necessary cause of cervical cancer, the fourth most common cancer and cause of cancer-related death in females worldwide. HPV also causes anal, vaginal, vulvar, penile, and oropharyngeal cancer. Prophylactic HPV vaccines based on recombinantly expressed virus-like particles have been developed. Two first-generation, U.S. Food and Drug Administration (FDA)-approved vaccines prevent infections and disease caused by HPV16 and HPV18, the two HPV genotypes that cause approximately 70% of cervical cancer, and one of these vaccines also prevents HPV6 and HPV11, the two HPV genotypes that cause 90% of genital warts. A next-generation vaccine, recently approved by the U.S. FDA, targets HPV16, HPV18, and five additional HPV genotypes that together causes approximately 90% of cervical cancer as well as HPV6 and HPV11. In clinical trials, these vaccines have shown high levels of efficacy against disease and infections caused by the targeted HPV genotypes in adolescent females and males and older females. Data indicate population effectiveness, and therefore cost effectiveness, is highest in HPV-naive young females prior to becoming sexually active. Countries that implemented HPV vaccination before 2010 have already experienced decreases in population prevalence of targeted HPV genotypes and related anogenital diseases in women and via herd protection in heterosexual men. Importantly, after more than 100 million doses given worldwide, HPV vaccination has demonstrated an excellent safety profile. With demonstrated efficacy, cost-effectiveness, and safety, universal HPV vaccination of all young, adolescent women, and with available resources at least high-risk groups of men, should be a global health priority. Failure to do so will result in millions of women dying from avertable cervical cancers, especially in low- and middle-income countries, and many thousands of women and men dying from other HPV-related cancers.
AB - Human papillomavirus (HPV) is the necessary cause of cervical cancer, the fourth most common cancer and cause of cancer-related death in females worldwide. HPV also causes anal, vaginal, vulvar, penile, and oropharyngeal cancer. Prophylactic HPV vaccines based on recombinantly expressed virus-like particles have been developed. Two first-generation, U.S. Food and Drug Administration (FDA)-approved vaccines prevent infections and disease caused by HPV16 and HPV18, the two HPV genotypes that cause approximately 70% of cervical cancer, and one of these vaccines also prevents HPV6 and HPV11, the two HPV genotypes that cause 90% of genital warts. A next-generation vaccine, recently approved by the U.S. FDA, targets HPV16, HPV18, and five additional HPV genotypes that together causes approximately 90% of cervical cancer as well as HPV6 and HPV11. In clinical trials, these vaccines have shown high levels of efficacy against disease and infections caused by the targeted HPV genotypes in adolescent females and males and older females. Data indicate population effectiveness, and therefore cost effectiveness, is highest in HPV-naive young females prior to becoming sexually active. Countries that implemented HPV vaccination before 2010 have already experienced decreases in population prevalence of targeted HPV genotypes and related anogenital diseases in women and via herd protection in heterosexual men. Importantly, after more than 100 million doses given worldwide, HPV vaccination has demonstrated an excellent safety profile. With demonstrated efficacy, cost-effectiveness, and safety, universal HPV vaccination of all young, adolescent women, and with available resources at least high-risk groups of men, should be a global health priority. Failure to do so will result in millions of women dying from avertable cervical cancers, especially in low- and middle-income countries, and many thousands of women and men dying from other HPV-related cancers.
KW - Human papillomavirus (HPV)
KW - vaccine-preventable diseases
KW - vaccines
KW - virology (human) and epidemiology
UR - http://www.scopus.com/inward/record.url?scp=84960387103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960387103&partnerID=8YFLogxK
U2 - 10.1017/S0950268815002198
DO - 10.1017/S0950268815002198
M3 - Review article
C2 - 26429676
AN - SCOPUS:84960387103
VL - 144
SP - 449
EP - 468
JO - Journal of Hygiene
JF - Journal of Hygiene
SN - 0950-2688
IS - 3
ER -